France· FR:65419708
EVEROLIMUS ARROW 2,5 mg, comprimé
A medicinal product containing évérolimus, registered in France by EUGIA PHARMA (MALTA) (MALTE), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- ÉVÉROLIMUS
- Manufacturer
- EUGIA PHARMA (MALTA) (MALTE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400930152621plaquette(s) polyamide aluminium PVC-Aluminium de 30 comprimé(s)EUR 455.98
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Évérolimus in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsAfinitor 2,5 mg, tablettenNovartis Europharm Limited
- United StatesAfinitorNovartis Pharmaceuticals Corporation
- CzechiaAFINITORNovartis Europharm Limited, Dublin
- SpainEVEROLIMUS ACCORD 2,5 MG COMPRIMIDOS EFGAccord Healthcare S.L.U.
- SwedenAfinitor 2,5 mg TablettNovartis Europharm Limited
- FinlandAfinitorNovartis Europharm Limited
- United KingdomAfinitor 2.5mg tabletsNovartis Pharmaceuticals UK Ltd
- CanadaAFINITORNOVARTIS PHARMACEUTICALS CANADA INC
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Certican, Everolimus Ethypharm
- Belgium · Certican, Everolimus Eg
- Bulgaria · Еверолимус Крка, Еверолимус Майлан
- Cyprus · Certican, Everolimus Pharmazac
- Czechia · Certican, Everolimus Accord
- Germany · Certican, Everofin
- Denmark · Certican, Everolimus Krka
- Estonia · Certican, Everolimus Krka
- Spain · Certican, Everolimus Accord
- Finland · Aderolio, Certican
- United Kingdom (Northern Ireland) · Aderolio, Aderolio 250 Mcg Tablets
- Greece · Certican, Everolimus Faran
- Croatia · Certican, Everolimus Krka
- Hungary · Certican, Everolimus Accord
- Ireland · Certican, Everolimus Tad
- Iceland · Afinitor, Certican
- Italy · Certican, Everolimus Accord
- Liechtenstein · Afinitor, Votubia
- Lithuania · Certican, Everolimus Norameda
- Luxembourg · Certican, Everolimus Eg
- Latvia · Certican, Everolimus Norameda
- Malta · Certican, Everolimus Ascend
- Netherlands · Certican, Certican Dispers
- Norway · Afinitor, Certican
- Poland · Aderolio, Certican
- Portugal · Certican, Everolimus Ethypharm
- Romania · Certican, Everolimus Accord
- Sweden · Certican, Everolimus Avansor
- Slovenia · Certican, Everolimus Krka
- Slovakia · Certican, Everolimus Accord
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ac437e12-ffb3-4d90-8ac5-a2df71ef0381 GET /v1/drugs/ac437e12-ffb3-4d90-8ac5-a2df71ef0381?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "65419708",
"date_amm": "2018-07-03",
"type_amm": "Procédure décentralisée",
"numero_ue": null,
"substance": "ÉVÉROLIMUS",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about évérolimus.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.